Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders

Abstract

Objective: To determine how the use of the newer, so called atypical antipsychotic medications, effects the pharmacoeconomic treatment burden of schizophrenia and related conditions and to provide a clear comparison of the costs and risks associated with these atypical drugs. Method: In this 2‐year, open‐label, prospective study, resource utilization (RU) data were collected on 160 patients with these conditions. A comparison between risks and costs was performed by combining the generalized CNOMSS data on both economic factors and risk assessments. Results: The main findings of the study were that the total adjusted 1‐ and 2‐year costs were lowest for quetiapine. Drug acquisition costs were lowest for risperidone for both the 1‐ and 2‐year cohorts. Clozapine use was predictably associated with the highest overall and medication costs at both 1 and 2 years. Conclusion: Treatment with risperidone or quetiapine was associated with the lowest overall costs when compared with olanzapine or clozapine.